Atout Organisation Science 18th International Workshop on Multiple Endocrine Neoplasia and other Rare Endocrine Tumors 2023

Categories: - MedS, Atout Organisation Science (WorldMEN CME), Endocrinology & Nutrition, Hematology, Internal Medicine, Oncology Tags: adrenal tumors MEN, adult endocrine tumors, adult MEN pathways, advanced MRI MEN, advanced practice provider endocrine, advanced practice providers, age-based MEN screening, Atout clinical care MEN, Atout endocrine conference, Atout endocrine neoplasia, Atout international workshop, Atout medical workshop, Atout MEN conference, Atout MEN education, Atout MEN event, Atout MEN workshop, Atout MEN1 MEN2 MEN4, Atout Organisation Science, Atout Organisation Science 2023, Atout Organisation Science MEN, Atout Organisation Science workshop, Atout rare endocrine tumors, biochemical work-up adrenal, biochemical workup MEN, biomarker-driven trials MEN, cascade genetic testing, cascade testing MEN, CDKN1B mutations, clinical trials MEN, corticotropinoma MEN, corticotropinomas MEN, CT protocols MEN, Endocrine, endocrine neoplasia conference, endocrine neoplasms, endocrine nurses, endocrine research conference MEN workshop 2023, endocrine surgeons, endocrine surgery training, endocrine tumor management workshop, endocrine tumor surveillance, endocrine tumor workshop, endocrinologists, entero-pancreatic NETs, fertility MEN, functional NET syndromes, functional syndromes NETs, Ga-68 PET MEN, genetic counseling endocrine tumors, genetic counseling MEN, genetic testing in MEN, genetic testing MEN, genetics-driven management adrenal, genetics-driven management MEN, genotype-based screening, genotype-based surveillance, hyperparathyroidism MEN, imaging algorithms MEN, immunotherapy MEN, INTERNAL MEDICINE, international collaborations MEN endocrinology course, international MEN collaborations, international MEN workshop, medical geneticists, medical genetics course, medullary thyroid carcinoma MEN, MEN biomarkers, MEN clinical care course, MEN clinical controversies, MEN educational event, MEN genetics workshop, MEN imaging algorithms, MEN multidisciplinary meeting, MEN re-operation strategies, MEN registries, MEN research conference, MEN research workshop, MEN researchers, MEN surveillance, MEN surveillance strategies, MEN syndrome education, MEN tumor board, MEN tumor board Atout Organisation Science, MEN workshop 2023, MEN1, MEN1 MEN2 MEN4 course, MEN1 MEN2 MEN4 symposium, MEN2, MEN4, minimally invasive endocrine surgery, molecular profiling MEN, molecular signatures MEN, molecular signatures therapy, mosaicism MEN, MTC biomarkers, MTC MEN, mTOR inhibitors MEN, multiple endocrine neoplasia, neck dissection MEN, NET grading, NET localization, nuclear medicine education, nuclear medicine specialists, oncologists, Oncology, oncology education, organ-preserving surgery MEN, pancreatic neuroendocrine tumors, paraganglioma MEN, parathyroid surgery MEN, pathologists, Pathology, pathology MEN, pathology MEN tumors, pediatric endocrine tumors, pediatric endocrinologists, pediatric MEN management, perioperative care MEN, pheochromocytoma MEN, pituitary surgery, pituitary surgery MEN, pituitary tumors MEN, pregnancy MEN, prolactinoma MEN, prolactinomas MEN, prophylactic thyroidectomy MEN, PRRT therapy, psychosocial support MEN, radiologists, radiology, rare endocrine tumor conference, rare endocrine tumor course, rare endocrine tumors, rare MEN-associated tumors, rare tumor CME, re-operation parathyroid, recurrence management pituitary, RET mutations, risk stratification MEN, somatotropinoma MEN, somatotropinomas MEN, SSTR imaging MEN, surveillance MEN tumors, systemic therapy MTC, targeted therapies NETs, therapeutic thyroidectomy MEN, thymic tumors MEN, TKI therapy MEN, TKIs MEN, transition pediatric to adult MEN, transition pediatric to adult MEN care, variant interpretation genetics, VEGF inhibitors MEN, WHO classification endocrine tumors, WHO classification MEN Brand: CMEMEDCOM

Description

Atout Organisation Science 18th International Workshop on Multiple Endocrine Neoplasia and other Rare Endocrine Tumors 2023

Include: 15 videos + 1 pdf, size: 14.48 GB

The 18th International Workshop on Multiple Endocrine Neoplasia (MEN) and Other Rare Endocrine Tumors 2023, organized by Atout Organisation Science, is a high-level scientific meeting dedicated to advancing clinical care and research for MEN1, MEN2, MEN4, and related rare endocrine neoplasms. Through expert keynotes, multidisciplinary panels, and case-based discussions, the workshop delivers cutting-edge insights spanning genetics, diagnostics, targeted therapies, and long-term management—designed for immediate impact in practice.

What You Will Learn

How to integrate contemporary genetic testing and counseling into MEN and rare endocrine tumor care
Best practices in surveillance strategies (age- and genotype-tailored) for high-risk patients and families
Nuanced diagnostic pathways using biochemistry, imaging, and pathology to differentiate complex presentations
Therapeutic decision-making across surgery, systemic/targeted therapy, and active surveillance
Multidisciplinary coordination for lifelong follow-up, transition of care, and quality-of-life optimization
Interpretation of emerging evidence, trials, and guidelines to personalize treatment

Event Details

Event: 18th International Workshop on MEN & Other Rare Endocrine Tumors 2023
Format: Sessions available on demand (where applicable)
Program Highlights: Expert roundtables, tumor boards, clinical controversies debates, young-investigator sessions, and networking opportunities with global leaders

Who Should Attend
Endocrinologists, endocrine surgeons, oncologists, medical geneticists, nuclear medicine specialists, radiologists, pathologists, pediatric endocrinologists, advanced practice providers, nurses, and researchers focusing on MEN syndromes and rare endocrine tumors. Trainees and early-career investigators seeking mentorship and exposure to state-of-the-art care are especially welcome.

Why Attend
This workshop uniquely concentrates world-class expertise on a challenging, often under-represented disease area. Attendees gain practical frameworks for complex decision-making, up-to-date knowledge on genetic and therapeutic advances, and a global network for collaboration—returning to clinic with clearer pathways to deliver safer, more precise, patient-centered care.

Topics:

Genetics & Counseling: MEN1, RET (MEN2), CDKN1B (MEN4), mosaicism, variant interpretation, cascade testing
Screening & Surveillance: Age- and genotype-based schedules; pediatric vs adult pathways; imaging algorithms
Parathyroid Disease: Hyperparathyroidism in MEN—indications, extent of surgery, re-operation strategies
Pituitary Tumors: Prolactinomas, somatotropinomas, corticotropinomas—medical therapy vs surgery, recurrence management
Pancreatic/Entero-Pancreatic NETs: Localization, grading, surgical timing, PRRT and targeted therapies, functional syndromes
Adrenal & Pheochromocytoma/Paraganglioma: Biochemical work-up, imaging, perioperative care, genetics-driven management
Medullary Thyroid Carcinoma (MTC): Prophylactic vs therapeutic thyroidectomy, neck dissection, systemic options, biomarkers
Thymic & Other Rare MEN-Associated Tumors: Risk stratification, surveillance, management nuances
Imaging & Nuclear Medicine: Ga-68/64 PET, SSTR imaging, advanced MRI/CT protocols for MEN surveillance
Pathology & Molecular Profiling: WHO classifications, grading, molecular signatures guiding therapy
Systemic/Targeted Therapies: TKIs, mTOR/VEGF pathway inhibitors, PRRT, immunotherapy prospects
Surgical Innovation: Minimally invasive approaches, re-do surgery, organ-preserving strategies
Life-Course Care & QOL: Transition from pediatric to adult care, fertility/pregnancy considerations, psychosocial support
Clinical Trials & Future Directions: Biomarker-driven designs, real-world evidence, registries, and international collaborations